Pregabalin

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Retrieved on: 
Monday, February 26, 2024

WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company’s Chief Commercial Officer.

Key Points: 
  • WATERTOWN, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Pamela Stephenson, MPH as the company’s Chief Commercial Officer.
  • “We are delighted to welcome an accomplished leader such as Pamela to Disc, where her breadth of commercial experience and acumen will be instrumental as the company continues to grow,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc.
  • Most recently, she served as the Chief Commercial Officer of Albireo, which was acquired by Ipsen, spearheading the successful launch of Bylvay for a rare cholestatic liver disease.
  • The Inducement Award was approved by Disc’s Board of Directors (the “Board”), including a majority of the independent directors serving on the Board.

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024

THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
  • “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
  • The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
  • Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
    Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Retrieved on: 
Wednesday, December 27, 2023

The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.

Key Points: 
  • The patent, once granted, will not expire until at least 2034 and will become part of Vistagen’s global patent portfolio on therapeutic uses and manufacturing techniques for AV-101.
  • In the study, AV-101 prodrug was systematically administered in four rat models of pain to examine its analgesic and behavioral profile.
  • The preclinical study was conducted by Tony L. Yaksh, PhD, Professor of Anesthesiology and Pharmacology at the University of California, San Diego.
  • Vistagen plans to seek potential strategic collaborations to further advance the clinical development and commercialization of AV-101.

Anavo Therapeutics Strengthens Management Team

Retrieved on: 
Thursday, September 21, 2023

Dr. McNulty will oversee the implementation of Anavo’s strategy from discovery into clinical development and, together with Dr. Quattropani and Anavo’s management team, the continued design of Anavo’s first- and best-in-class phosphatase-targeting allosteric modulators.

Key Points: 
  • Dr. McNulty will oversee the implementation of Anavo’s strategy from discovery into clinical development and, together with Dr. Quattropani and Anavo’s management team, the continued design of Anavo’s first- and best-in-class phosphatase-targeting allosteric modulators.
  • “We are fortunate to welcome Anna and Shaun to the Anavo team at this stage of our company’s growth,” said Birgit Zech, PhD, Chief Executive Officer of Anavo Therapeutics.
  • “Anavo’s IGNITE platform uniquely enables the rapid identification and development of therapeutics targeting phosphatases, initially thought to be undruggable targets,” said Dr. McNulty.
  • “I am excited to join the Anavo team as we continue to accelerate our proprietary portfolio of programs targeting disease-relevant phosphatases toward clinical development and to build out our next-generation approach for phosphatase targeting.”
    Anna Quattropani, PhD, joins Anavo with over 20 years of experience in medicinal chemistry and drug discovery.

How drugs can warp your sense of time

Retrieved on: 
Thursday, August 10, 2023

Where trips to the dentist flew by in a second and holidays felt like they lasted forever.

Key Points: 
  • Where trips to the dentist flew by in a second and holidays felt like they lasted forever.
  • Time altering pills may sound like science fiction but the time warping effects of psychoactive drugs suggest that deliberate time manipulation may be possible.
  • Other drugs can scramble our sense of time completely.
  • Pregabalin, a drug used to treat epilepsy and anxiety, and anti-anxiety drug Xanax, both slow
    the passage of time.

So why do drugs warp time?

    • Drugs associated with increases in the passage of time are stimulants, which cause increased activity and excitation across the areas of the brain associated with cognitive function.
    • Drugs also affect behaviour and emotions, both of which can twist our experience of time.
    • Drugs such as cocaine and MDMA can have powerful effects on mood, inducing feelings of happiness and euphoria.
    • What you do while taking drugs will contribute to the sensation that time is bending.

The aftermath

    • The neurochemical, emotional and cognitive effects of comedowns create the perfect environment for time to drag.
    • The combination of exhaustion and low mood means that much of the recovery period is spent wondering “when will this end”, which also exaggerates the slowing of time.

Intertwined with human history and nature

    • They involve drinking a liquid brewed from leaves from the Psychotria viridis shrub and stalks of the Banisteriopsis caapi vine.
    • The brew causes changes in the state of consciousness, resulting in hallucinations and a significant change in the flow of time.
    • Nowadays, ayahuasca ceremonies attract tourists from across the world seeking to experience altered states of consciousness and spirituality.
    • Ruth Ogden receives funding from receives funding from The British Academy, The Wellcome Trust, The Economic and Social Research Council and CHANSE.

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Ellen Brett, Marketing and Growth Strategist, Joins HawkPartners

Retrieved on: 
Wednesday, January 11, 2023

BOSTON, Jan. 11, 2023 /PRNewswire/ -- HawkPartners, a marketing consulting firm providing advisory services at the intersection of marketing strategy and customer insights, announced that Ellen Brett has joined the firm as a Partner.

Key Points: 
  • BOSTON, Jan. 11, 2023 /PRNewswire/ -- HawkPartners, a marketing consulting firm providing advisory services at the intersection of marketing strategy and customer insights, announced that Ellen Brett has joined the firm as a Partner.
  • Ellen's unique ability to diagnose and optimize strategies for brands allows them to maximize new growth opportunities.
  • Her achievements at Pfizer® propelled her to the firm's most senior marketing leadership position, with responsibility for $13B in product revenues.
  • "Ellen's unique ability to diagnose and optimize strategies for brands allows them to maximize new growth opportunities," expressed Scott Berman, co-founder of HawkPartners.

Global Peripheral Neuropathy Market Report 2022: High Prevalence of Chronic Neuropathic Pain Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, October 31, 2022

The report offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2022 to 2030.

Key Points: 
  • The report offers strategic insights into the overall Peripheral Neuropathy market along with the market size and estimates for the duration 2022 to 2030.
  • The drug types studied for analyzing the overall global peripheral neuropathy market are segmented into pharmacological therapies and non-pharmacological therapies.
  • Among antidepressants, Amitriptyline is widely recommended for neuropathic pain and thus dominates the peripheral neuropathy antidepressant market.
  • Asia Pacific would exhibit the fastest growth rate in the Global Peripheral Neuropathy market due to aging population, increasing health awareness and high prevalence of the diabetes, cancer and HIV/AIDS.

Global Pregabalin Market to Grow by $153.03 Million During 2022-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 14, 2022

The "Global Pregabalin Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pregabalin Market 2022-2026" report has been added to ResearchAndMarkets.com's offering.
  • The pregabalin market is poised to grow by $153.03 mn during 2022-2026, accelerating at a CAGR of 3.74% during the forecast period.
  • The report on the pregabalin market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment.